Area covered by CXCL10+ epithelial cells was significantly larger in intermediate (453,886.16 ± 177,813.12, p = 0.0031) and advanced prostate cancer patients (713,643.42 ± 242,242.98, p = 0.0003), compared to patients with PIN (102,605.8 ± 89,134.77) or evanescent carcinoma (64,537.8 ± 52,063.40, Eva Ca vs Int: p = 0.0011, Eva Ca vs Adv: p = 0.0002) (Figure S2 in Supplementary Material). This evidence concerns the gene CXCL10 and prostate cancer.